On April 25, 2023 AnHorn Medicines, a private biotechnology company focused on the development of precision medicines for degrading disease-causing proteins, reported the successful completion of a $10 million Series A financing (Press release, AnHorn Medicines, APR 25, 2023, View Source [SID1234632788]). This financing will enable AnHorn Medicines to expedite the growth of its pipeline, advance development of drug candidates, and enhance its platform capabilities to rationally design bi-functional degraders and molecular glues that target the known drivers of cancers and other diseases currently unaddressed by conventional methods.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Series A financing was led by Taiwania Capital with participation from new investors included TaiAn Technologies, Industrial Technology Investment Corporation, Hong Tai Electric Industrial, Black Marble Capital Management, Mega Venture Capital and Sunplus Technology.

In addition to financial resources, this round of investment brings impressive experience and intellectual resources to AnHorn Medicines in the form of two new members of the Board of Directors:

Bryan Kao, Ph.D., Sr. Investment Manager, Taiwania Capital;

Jo Shen, Ph.D., Common Director;

Chu-Chiang Lin, Ph.D., President and Chief Executive Officer of AnHorn Medicines.

"We are pleased to have the support of this strong group of investors who share our vision and believe in our approach to expand the field of protein degradation into a broader array of diseases." said Chu-Chiang Lin, Ph.D., CEO of AnHorn Medicines.

AnHorn Medicines has built a next-generation protein degradation platform with highly focused and scalable chemical libraries that target critical disease-causing proteins. The team comprise diverse specialties which consists of medicinal chemistry, structural biology, machine learning-based chemistry, and pharmacology.